Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Treatment development targeting Hippo pathway for scirrhous type gastric cancer.
Authors
Yuichiro Miki
Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
Yuichiro Miki , Mami Yoshii , Kenji Kuroda , Hironari Miyamoto , Tatsuro Tamura , Takahiro Toyokawa , Shigeru Lee , Kiyoshi Maeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 398)
DOI
10.1200/JCO.2024.42.3_suppl.398
Abstract #
398
Poster Bd #
K3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center.
First Author: Jetty A.M. Weijers
Poster
2023 ASCO Annual Meeting
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
First Author: Susumu Okano
Poster
2023 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
First Author: Subotheni Thavaneswaran
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen